Literature DB >> 32557848

Graphical approaches for the control of generalized error rates.

David S Robertson1, James M S Wason1,2, Frank Bretz3,4.   

Abstract

When simultaneously testing multiple hypotheses, the usual approach in the context of confirmatory clinical trials is to control the familywise error rate (FWER), which bounds the probability of making at least one false rejection. In many trial settings, these hypotheses will additionally have a hierarchical structure that reflects the relative importance and links between different clinical objectives. The graphical approach of Bretz et al (2009) is a flexible and easily communicable way of controlling the FWER while respecting complex trial objectives and multiple structured hypotheses. However, the FWER can be a very stringent criterion that leads to procedures with low power, and may not be appropriate in exploratory trial settings. This motivates controlling generalized error rates, particularly when the number of hypotheses tested is no longer small. We consider the generalized familywise error rate (k-FWER), which is the probability of making k or more false rejections, as well as the tail probability of the false discovery proportion (FDP), which is the probability that the proportion of false rejections is greater than some threshold. We also consider asymptotic control of the false discovery rate, which is the expectation of the FDP. In this article, we show how to control these generalized error rates when using the graphical approach and its extensions. We demonstrate the utility of the resulting graphical procedures on three clinical trial case studies.
© 2020 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  false discovery proportion; generalized familywise error rate; hypothesis testing; multiple comparison procedures; multiple endpoints

Mesh:

Year:  2020        PMID: 32557848      PMCID: PMC7612110          DOI: 10.1002/sim.8595

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  18 in total

1.  A recycling framework for the construction of Bonferroni-based multiple tests.

Authors:  C-F Burman; C Sonesson; O Guilbaud
Journal:  Stat Med       Date:  2009-02-28       Impact factor: 2.373

2.  General multistage gatekeeping procedures.

Authors:  Alex Dmitrienko; Ajit C Tamhane; Brian L Wiens
Journal:  Biom J       Date:  2008-10       Impact factor: 2.207

3.  Using prior information to allocate significance levels for multiple endpoints.

Authors:  P H Westfall; A Krishen; S S Young
Journal:  Stat Med       Date:  1998-09-30       Impact factor: 2.373

4.  Structured multiplicity and confirmatory statistical analyses in pharmacodynamic studies using the quantitative electroencephalogram.

Authors:  Georg Ferber; Luc Staner; Peter Boeijinga
Journal:  J Neurosci Methods       Date:  2011-07-18       Impact factor: 2.390

5.  A multiple testing method for hypotheses structured in a directed acyclic graph.

Authors:  Rosa J Meijer; Jelle J Goeman
Journal:  Biom J       Date:  2014-11-13       Impact factor: 2.207

6.  Applications of general multistage gatekeeping and graphical multiple testing strategies in a clinical trial setting.

Authors:  Yihan Li; Xin Wang; Deli Wang; Walter Offen
Journal:  Contemp Clin Trials       Date:  2018-10-19       Impact factor: 2.226

7.  Memory and other properties of multiple test procedures generated by entangled graphs.

Authors:  Willi Maurer; Frank Bretz
Journal:  Stat Med       Date:  2012-12-28       Impact factor: 2.373

8.  Type-II generalized family-wise error rate formulas with application to sample size determination.

Authors:  Phillipe Delorme; Pierre Lafaye de Micheaux; Benoit Liquet; Jérémie Riou
Journal:  Stat Med       Date:  2016-02-23       Impact factor: 2.373

9.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Authors:  Henry Krum; Barry Massie; William T Abraham; Kenneth Dickstein; Lars Kober; John J V McMurray; Ashkay Desai; Claudio Gimpelewicz; Albert Kandra; Bernard Reimund; Henning Rattunde; Juergen Armbrecht
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

10.  Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

Authors:  John R Teerlink; Marco Metra; G Michael Felker; Piotr Ponikowski; Adriaan A Voors; Beth Davison Weatherley; Alon Marmor; Amos Katz; Jacek Grzybowski; Elaine Unemori; Sam L Teichman; Gad Cotter
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.